Wire · opportunities
FDA Approves Zanvastro
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
Ionis Pharmaceuticals received FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, an ultra-rare progressive leukodystrophy. The RNA-targeted antisense therapy, administered quarterly, demonstrated clinical benefit in stabilizing gait and improving motor function, and the approval includes a Rare Pediatric Disease Priority Review Voucher.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 3 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
Approval of Zanvastro opens a rare disease market that was previously untapped, offering you a chance to develop or partner in ultra-rare neurodegenerative therapies. The priority review voucher signals broader FDA support, which you should leverage to accelerate regulatory strategy.
◆ Coverage
15 sources · first reported 3 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics